Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning

被引:0
|
作者
Valle, Leonardo Guedes Moreira [1 ]
Cunha, Marcela Juliano Silva [1 ]
Schmid, Bruno Pagnin [1 ]
Falsarella, Priscila Mina [1 ]
de Rezende, Marcelo Bruno [1 ]
Felga, Guilherme Eduardo Goncalves [1 ]
Ogawa, Renata Emy [1 ]
Garcia, Rodrigo Gobbo [1 ]
Affonso, Breno Boueri [1 ]
Nasser, Felipe [1 ]
Galastri, Francisco Leonardo [1 ]
机构
[1] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
来源
EINSTEIN-SAO PAULO | 2023年 / 21卷
关键词
Living donors; Liver neoplasms; Carcinoma; hepatocellular; Chemoembolization; therapeutic; Neoadjuvant therapy; Response evaluation criteria in solid tumors; Radiology; interventional; TRANSARTERIAL CHEMOEMBOLIZATION;
D O I
10.31744/einstein_journal/2023AO0307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the radiological characteristics of hepatocellular carcinoma (HCC) lesions that achieved a complete response following drug-eluting bead transarterial chemoembolization (DEB-TACE) preceding liver transplantation. Methods: This single-center case-control study enrolled patients with hepatocellular carcinoma who underwent neoadjuvant DEB-TACE therapy, were followed up with contrast-enhanced magnetic resonance imaging or computed tomography, and were successively evaluated according to the modified Response Evaluation Criteria in Solid Tumors. The HCCs were divided into two groups based on their diameter (Group A: <= 3cm; Group B: 3cm). Viability was assessed using the Kaplan-Meier method according to tumor size categories. The relationship between tumor variables was analyzed using bivariate Cox regression.Results: Three-hundred and twenty-eight patients with 667 hepatocellular carcinomas who underwent their first DEB-TACE session were enrolled. A total of 105 hepatocellular carcinomas in 59 patients exhibited complete response after the initial DEB-TACE session and were divided into Group A (92 HCCs) and Group B (13 HCCs). The diameter in Group A decreased significantly compared to the pre-procedure size until the second assessment (p<0.001), with no subsequent reduction in diameter, despite maintaining a complete response. In Group B, the reduction in diameter remained significant compared with the initial value until the sixth imaging evaluation (p=0.014). The average reduction was 45.1% for Group B and a maximum of 14.9% in Group A.Conclusion: HCCs >3cm exhibited a greater reduction in size and a longer time to recurrence. HCCs <= 3cm had a shorter relapse time. The recurrence rates were similar. These findings may aid in planning for liver transplantation.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma
    Facciorusso, Antonio
    Mariani, Luigi
    Sposito, Carlo
    Spreafico, Carlo
    Bongini, Marco
    Morosi, Carlo
    Cascella, Tommaso
    Marchiano, Alfonso
    Camerini, Tiziana
    Bhoori, Sherrie
    Brunero, Federica
    Barone, Michele
    Mazzaferro, Vincenzo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (03) : 645 - 653
  • [22] Imaging Validation of Drug-Eluting Beads Transarterial Chemoembolization of Hepatocellular Carcinomas in Living Donor Liver Transplantation
    Tong, Y. S.
    Huang, T. L.
    Chen, T. Y.
    Tsang, L. L. C.
    Ou, H. Y.
    Yu, C. Y.
    Hsu, H. W.
    Xiong, L. W.
    Liao, C. C.
    Eng, H. L.
    Chen, C. L.
    Cheng, Y. F.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (09) : 2622 - 2625
  • [24] Tumor Response and Nomogram-Based Prognostic Stratification for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization
    Ji, Kun
    Zhu, Hanlong
    Wu, Wei
    Li, Xin
    Zhan, Pengchao
    Shi, Yang
    Sun, Junhui
    Li, Zhen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 537 - 551
  • [25] Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
    Baur, Johannes
    Ritter, Christian O.
    Germer, Christoph-Thomas
    Klein, Ingo
    Kickuth, Ralph
    Steger, Ulrich
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2016, 8 : 69 - 74
  • [26] Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma
    Cao, Wen-Zhen
    Zhou, Zhu-Qian
    Jiang, Song
    Li, Hao
    Niu, Wei
    Gao, Peng
    Li, Gui-Jie
    Chen, Feng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (06) : 4625 - 4630
  • [27] Comparison of Callisphere Drug-Eluting Beads Transarterial Chemoembolization and Conventional Transarterial Chemoembolization for the treatment of Hepatocellular Carcinoma
    Ren, Yongjun
    Zhao, Caixia
    Xiong, Yongfu
    Liu, Zhongbai
    Wu, Guo
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (03) : 303 - 307
  • [28] Safety and Effectiveness of Chemoembolization with Drug-Eluting Beads for Advanced-Stage Hepatocellular Carcinoma
    Sanjeeva P. Kalva
    Melina Pectasides
    Raymond Liu
    Niranjan Rachamreddy
    Shravani Surakanti
    Kalpana Yeddula
    Suvranu Ganguli
    Stephan Wicky
    Lawrence S. Blaszkowsky
    Andrew X. Zhu
    CardioVascular and Interventional Radiology, 2014, 37 : 381 - 387
  • [29] Safety and Effectiveness of Chemoembolization with Drug-Eluting Beads for Advanced-Stage Hepatocellular Carcinoma
    Kalva, Sanjeeva P.
    Pectasides, Melina
    Liu, Raymond
    Rachamreddy, Niranjan
    Surakanti, Shravani
    Yeddula, Kalpana
    Ganguli, Suvranu
    Wicky, Stephan
    Blaszkowsky, Lawrence S.
    Zhu, Andrew X.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2014, 37 (02) : 381 - 387
  • [30] D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma
    Duan, Youjia
    Hou, Xiaopu
    Guo, Jiang
    Li, Honglu
    Cai, Liang
    Cheng, Long
    Zhao, Wenpeng
    Shao, Xihong
    Du, Hongliu
    Diao, Zhenying
    Li, Changqing
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (04)